Pharmacological treatments for cutaneous manifestations of inherited ichthyoses
Authors:
- Hernán CortésHernán Cortés
- María L. Del Prado-AudeloMPMaría L. Del Prado-Audelo
- Zaida Urbán-MorlánZUZaida Urbán-Morlán
- Sergio Alcalá-AlcaláSergio Alcalá-Alcalá
- Maykel González-TorresMGMaykel González-Torres
- Octavio D. Reyes-HernándezOROctavio D. Reyes-Hernández
- Manuel González-Del CarmenMCManuel González-Del Carmen
- Gerardo Leyva-GómezGerardo Leyva-Gómez
- 17 October 2019
- journal article
- review article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 312 (4) , 237-248
Abstract
Inherited ichthyoses are a group of etiologically heterogeneous diseases that affect the function of the skin and that are classified as syndromic and non-syndromic entities. Irrespective of the type, all these disorders are generally produced by mutations in genes involved in a variety of cellular functions in the skin. These mutations lead to disruption of the stratum corneum and impairment of the skin barrier, producing clinical features such as hyperkeratosis, skin scaling, erythema, fissures, pruritus, inflammation, and skin pain. Despite advances in the knowledge of the pathogenesis of ichthyoses, there is, to our knowledge, no definitive cure for skin manifestations, and current treatments consist of moisturizers, emollients, and keratolytic agents. In this respect, the development of new formulations based on nanotechnology could be useful to enhance their therapeutic effectiveness. In this article, we provide a comprehensive description of pharmacological treatments for cutaneous manifestations in patients with inherited ichthyosis and discuss novel approaches with therapeutic potential for this purpose. Moreover, we offer an overview of toxicity concerns related to these treatments.Keywords
Funding Information
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (PAPIIT TA 200318)
This publication has 70 references indexed in Scilit:
- The roles of ABCA12 in epidermal lipid barrier formation and keratinocyte differentiationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2014
- Topical Tazarotene for the Treatment of Ectropion in IchthyosisJAMA Dermatology, 2013
- Successful experimental treatment of congenital ichthyosis in an infantBMJ Case Reports, 2013
- Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promiseExperimental Dermatology, 2012
- Association of glycerol and paraffin in the treatment of ichthyosis in children: an international, multicentric, randomized, controlled, double‐blind studyJournal of the European Academy of Dermatology and Venereology, 2011
- Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient creamCurrent Medical Research and Opinion, 2011
- Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Sorèze 2009Journal of the American Academy of Dermatology, 2010
- X-linked ichthyosis: An oculocutaneous genodermatosisJournal of the American Academy of Dermatology, 2010
- Emollients and keratolytics remain the mainstay of therapy for patients with ichthyosisDrugs & Therapy Perspectives, 2004
- Propylene glycol dermatitisJournal of the American Academy of Dermatology, 1991